These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18494748)

  • 1. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases.
    van Baal PH; van den Berg M; Hoogenveen RT; Vijgen SM; Engelfriet PM
    Value Health; 2008 Dec; 11(7):1033-40. PubMed ID: 18494748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach.
    Hertzman P
    Pharmacoeconomics; 2005; 23(10):1007-20. PubMed ID: 16235974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
    Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
    Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orlistat for the treatment of obesity: cost utility model.
    Foxcroft DR
    Obes Rev; 2005 Nov; 6(4):323-8. PubMed ID: 16246217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity.
    Forster M; Veerman JL; Barendregt JJ; Vos T
    Int J Obes (Lond); 2011 Aug; 35(8):1071-8. PubMed ID: 21224825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.
    Neovius M; Narbro K
    Int J Obes (Lond); 2008 Dec; 32(12):1752-63. PubMed ID: 18982009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis.
    Losina E; Smith KC; Paltiel AD; Collins JE; Suter LG; Hunter DJ; Katz JN; Messier SP
    Arthritis Care Res (Hoboken); 2019 Jul; 71(7):855-864. PubMed ID: 30055077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.
    Maetzel A; Ruof J; Covington M; Wolf A
    Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and Economic Impacts of the National Menu Calorie Labeling Law in the United States: A Microsimulation Study.
    Liu J; Mozaffarian D; Sy S; Lee Y; Wilde PE; Abrahams-Gessel S; Gaziano T; Micha R;
    Circ Cardiovasc Qual Outcomes; 2020 Jun; 13(6):e006313. PubMed ID: 32493057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.
    Lamotte M; Annemans L; Lefever A; Nechelput M; Masure J
    Diabetes Care; 2002 Feb; 25(2):303-8. PubMed ID: 11815500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
    Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
    Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a community-based weight control intervention targeting a low-socioeconomic-status Mexican-origin population.
    Wilson KJ; Brown HS; Bastida E
    Health Promot Pract; 2015 Jan; 16(1):101-8. PubMed ID: 24893680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluations of adult weight management interventions: a systematic literature review focusing on methods used for determining health impacts.
    Griffiths UK; Anigbogu B; Nanchahal K
    Appl Health Econ Health Policy; 2012 May; 10(3):145-62. PubMed ID: 22439628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.
    Panidis D; Tziomalos K; Papadakis E; Chatzis P; Kandaraki EA; Tsourdi EA; Katsikis I
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):432-8. PubMed ID: 23909452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies.
    Finkelstein EA; Verghese NR
    Clin Obes; 2019 Apr; 9(2):e12294. PubMed ID: 30677252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of treatment with orlistat in Italian obese patients.
    Iannazzo S; Zaniolo O; Pradelli L
    Curr Med Res Opin; 2008 Jan; 24(1):63-74. PubMed ID: 18021491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
    Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
    J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of rimonabant in the treatment of obesity.
    Hampp C; Hartzema AG; Kauf TL
    Value Health; 2008; 11(3):389-99. PubMed ID: 18179661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model.
    Foxcroft DR; Milne R
    Obes Rev; 2000 Oct; 1(2):121-6. PubMed ID: 12119985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.